We've been hearing about stem cells for treating disease for so many years. Finally, a 1st rate review to set the record straight, and future directions (perhaps a bit overly optimistic) https://t.co/VrxPZd83uR @NEJM by Helen Blau & @G_Q_Daley
Applications welcome for undergraduates interested in cardiovascular research. This 10 week summer program offers $7k stipend (co-sponsored by CVI and AHA).
https://t.co/37biE7yDPx
@AHA_Research @AHABayArea @AHASiliconV @AHAScience@StanfordVPUE
Out today! The mechanism that drives hypertrophic cardiomyopathy in MyBPC truncations and what we might be able to do about it. 'Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin' https://t.co/W3h4sgoVcW @wellcometrust@RDMOxford@harvardmed@ScienceTM
Begley from BioCurate discuss his experience from Amgen that >90% of the preclinical papers in journals like @sciencemagazine@CellCellPress@nature cannot be reproduced even by the same lab. Most are not due to fraud but from sloppy science with perverse incentives for success.
It is with sadness that I share with you that Constance Weinstein, the wonderful, and dynamic initiator of what we now call the Weinstein Cardiovascular Conference passed away on January 10th 2019. Our community owes her so much. Happy her name will live on with us all!
Words for the start of a new year: "If our optimism doesn't address the problems that affect so many of our fellow human beings, then our optimism needs more empathy." - @BillGates and @melindagates, delivering the Commencement address at Stanford in 2014
@AlexDainis So the company was originally a sequencing company, old tech, repackaged for 3 years and just before boards meeting, they came out with this story saying they r the first to do custom made human gene editing... huge money grab move
@AlexDainis There was an IRB for research grade but the actual expt and conception was done at private clinic. Chinese academy and group of stem cell biologists have all signed a letter condemning this behavior...